IN2012DN05143A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05143A
IN2012DN05143A IN5143DEN2012A IN2012DN05143A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A IN 5143DEN2012 A IN5143DEN2012 A IN 5143DEN2012A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A
Authority
IN
India
Prior art keywords
present
glioma
tbs40
nfl
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Joel Eyer
Alan Peterson
Julien Balzeau
Raphael Berges
Original Assignee
Univ Angers
Inst Nat Sante Rech Med
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Inst Nat Sante Rech Med, Univ Mcgill filed Critical Univ Angers
Publication of IN2012DN05143A publication Critical patent/IN2012DN05143A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN5143DEN2012 2009-12-14 2010-12-14 IN2012DN05143A (th)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (en) 2009-12-14 2009-12-14 Use of a neurofilament peptide for the treatment of glioma
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (1)

Publication Number Publication Date
IN2012DN05143A true IN2012DN05143A (th) 2015-10-23

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5143DEN2012 IN2012DN05143A (th) 2009-12-14 2010-12-14

Country Status (7)

Country Link
US (2) US9446092B2 (th)
EP (2) EP2332560A1 (th)
JP (1) JP5806679B2 (th)
CN (1) CN102821777B (th)
CA (1) CA2784091C (th)
IN (1) IN2012DN05143A (th)
WO (1) WO2011073207A1 (th)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP2959913A1 (en) * 2014-06-23 2015-12-30 Universite D'angers Use of a neurofilament peptide for targeting neural stem cells
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN108490191B (zh) * 2018-03-13 2019-04-16 首都医科大学附属北京地坛医院 神经丝蛋白轻链在梅毒血液检测中的应用
JP7480132B2 (ja) * 2018-10-12 2024-05-09 アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ.アー. 放射性標識されたgprpアンタゴニスト及び界面活性剤を含む医薬組成物
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4593865B1 (en) * 2022-09-30 2026-05-06 Gliocure Pharmaceutical composition comprising nfl-tbs40-63 peptide, variants or salts thereof and alanine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire

Also Published As

Publication number Publication date
JP2013513646A (ja) 2013-04-22
CN102821777B (zh) 2014-12-17
EP2512499B1 (en) 2015-09-16
US20130004429A1 (en) 2013-01-03
EP2512499A1 (en) 2012-10-24
US20170000846A1 (en) 2017-01-05
CA2784091C (en) 2020-08-11
CA2784091A1 (en) 2011-06-23
CN102821777A (zh) 2012-12-12
WO2011073207A1 (en) 2011-06-23
US9446092B2 (en) 2016-09-20
EP2332560A1 (en) 2011-06-15
JP5806679B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
NO20076401L (no) Diarylhydantoinforbindelser
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2009008461A (es) Variantes geneticas que contribuyen a riesgo de cancer de prostata.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010008021A (es) Nuevos derivados de n-(2-amino-fenil)-amida.
UA102115C2 (ru) Дизамещенные фталазиновые антагонисты сигнального пути hedgehog
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MY150600A (en) Use of opioid antagonists for treating urinary retention
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
IN2013MN01188A (th)
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.